Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1537-1546

  Copeland Jr , Robert L ^a   Das, Jharna R ^a   Bakare, Oladapo ^a   Enwerem, Nkechi M ^a   Berhe, Solomon ^a   Hillaire, Kenguele ^a   White, Douglas ^a   Beyene, Desta ^a   Kassim, Olakunle O ^a   Kanaan, Yasmine M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

2,3 Dichloro 5,8 dimethoxy 1,4 naphthoquinone; Apoptosis; Cell cycle; Cytotoxicity; Prostate cancer cell lines

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2,3 DICHLORO 5,8 DIMETHOXY 1,4 NAPHTHOQUINONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INCIDENCE; CELL CYCLE PROGRESSION; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; WESTERN BLOTTING;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MALE; NAPHTHOQUINONES; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN;

EID: 34249277456     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lewis TS, Shapiro PS and Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139, 1998.
2. Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997.
3. Biroccio A and Leonetti C: Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocr Relat Cancer 11: 407-421, 2004.
4. Dancey JE: Agents targeting ras signaling pathway. Curr Pharm 8: 2259-2267, 2002.
5. Kolch W: Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother 3: 709-718, 2002.
6. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC and Isaacs JT: Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473-480, 1995.
7. Pinski J, Parikh A, Bova GS and Isaacs JT: Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 61: 6372-6376, 2001.
8. Habib NS, Bekhit AA and Park JY: Synthesis and biological evaluation of some new substituted naphthoquinones. Boll Chim Farm 142: 232-238, 2003.
9. Chung Y, Shin YK, Zhan CG, Lee S and Cho H: Synthesis and evaluation of antitumor activity of 2- and 6-[(1,3-benzothiazol-2-yl)aminomethyl]-5,8- dimethoxy-1,4-naphthoquinone derivatives. Arch Pharm Res 27: 893-900, 2004.
10. Bakare O, Ashendel CL, Peng H, Zalkow LH and Burgess EM: Synthesis and MEK1 inhibitory activities of imido-substituted 2-chloro-1,4-naphthoquinones. Bioorg Med Chem 11: 3165-3170, 2003.
11. Huang LJ, Chang FC, Lee KH, Wang JP, Teng CM and Kuo SC: Synthesis and antiplatelet, antiinflammatory, and antiallergic activities of substituted 3-chloro-5,8-dimethoxy-1,4-naphthoquinone and related compounds. Bioorg Med Chem 6: 2261-2269, 1998.
12. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR Jr, Quinn DI and Neamati N: Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther 4: 1105-1113, 2005.
13. Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P and Zunino F: Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol 65: 1281-1294, 2003.
14. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
15. Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G and Zunino F: Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate 48: 254-264, 2001.
16. Bellezza I, Bracarda S, Caserta C and Minelli A: Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. Mol Genet Metab 88: 114-122, 2006.
17. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V and Cittadini A: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 201: 97-105, 2004.
18. Sun SY, Hail N Jr and Lotan R: Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96: 662-672, 2004.
19. Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949, 2004.
20. Nakagawa H, Tsuta K, Kiuchi K, Senzaki H, Tanaka K, Hioki K and Tsubura A: Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines, Carcinogenesis 22: 891-897, 2001.
21. Kwon H and Choung SY: Induction of differentiation of U-937 cells by 2-chloro-3-amino-1,4-naphthoquinone. Res Commun Mol Pathol Pharmacol 97: 215-227, 1997.
22. Ball MD, Bartlett MS, Shaw M, Smith JW, Nasr M and Meshnick SR: Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii. Antimicrob Agents Chemother 45: 1473-1479, 2001.
23. Chang HX, Chou TC, Savaraj N, Liu LF, Yu C and Cheng CC: Design of antineoplastic agents based on the "2-phenyl-naphthalene-type" structural pattern. 4. Synthesis and biological activity of 2-chloro-3- (substituted phenoxy)-1,4-naphthoquinones and related 5,8-dihydroxy-1,4- naphthoquinones. J Med Chem 42: 405-408, 1999.
24. Luk'ianova LD, Chernobaeva GN, Vlasova IG, Korneev AA, Popova OA and Zamula SV: The correction of energy metabolism disorders in hypoxia by using vitamin K. Eksp Klin Farmakol 55: 44-47, 1992.
25. Huang LJ, Chang FC, Lee KH, Wang JP, Teng CM and Kuo SC. Synthesis and antiplatelet, antiinflammatory, and antiallergic activities of substituted 3-chloro-5,8-dimethoxy-1,4-naphthoquinone and related compounds. Bioorg Med Chem 6: 2261-2269, 1998.
26. Ertl P, Cooper D, Allen G and Slater MJ: 2-chloro-3-substituted-1,4- naphthoquinone inactivators of human cytomegalovirus protease. Bioorg Med Chem Lett 9: 2863-2866, 1999.
27. Hellawell GO, Turner GDH, Davies DR, Poulsom R and Brewster SF: Expression of the Type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942-2950, 2002.
28. Pinches C, Peehl DM, Lamson G and Rosenfield RG: Insulin-like growth factor, IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cell. J Clin Endocrinol Metabol 73: 401-407, 1991.